REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment where a patient's own immune cells are modified in a lab to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not responded to prior thera…
Matched conditions: REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:35 UTC
-
New hope for hard-to-treat brain lymphoma: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called acalabrutinib in 49 people with central nervous system lymphoma that has returned or not responded to prior therapy. The goal is to find the safest dose and see how well it controls the cancer. Participants take the drug by mouth and are monitored f…
Matched conditions: REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 22, 2026 14:04 UTC